Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6

Phytomedicine

Volumn 16, Issue 2-3, 2009, Pages 161-171

  Michael, Sebastian ^a   Kelber, Olaf ^b   Hauschildt, Sunna ^a   Spanel Borowski, Katharina ^a   Nieber, Karen ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b Steigerwald Arzneimittelwerk GmbH   (Germany)

Author keywords

ACh contraction; Gastrointestinal motility; Iberis amara; Iberogast; Inflammation; Rat ileum

Indexed keywords

ACETYLCHOLINE; ANGELICA ROOT EXTRACT; ANTIINFLAMMATORY AGENT; CARVI FRUCTUS EXTRACT; CHELIDONII HERBA EXTRACT; IBERIS AMARA EXTRACT; IBEROGAST; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; LIQUIRITIAE RADIX EXTRACT; MATRICARIAE FLOS EXTRACT; MELISSAE FOLIUM EXTRACT; MESSENGER RNA; PEPPERMINT; PLANT EXTRACT; SILYBI MARIANI FRUCTUS EXTRACT; STW 5; STW 6; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARVI FRUCTUS; CELL ISOLATION; CHELIDONII HERBA; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IBERIS AMARA; ILEUM; IN VITRO STUDY; INFLAMMATION; INTESTINE CONTRACTION; JEJUNUM; LIQUIRITIAE RADIX; MALE; MATRICARIAE FLOS; MEDICINAL PLANT; MELISSAE FOLIUM; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SILYBI MARIANIFRUCTUS; SMALL INTESTINE DISEASE; WISTAR RAT;

ANGIOSPERMS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BRASSICACEAE; DRUG COMBINATIONS; HUMANS; ILEUM; INFLAMMATION; INTERLEUKIN-10; INTESTINAL MUCOSA; JEJUNUM; MALE; MODELS, ANIMAL; MONOCYTES; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, WISTAR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

IBERIS AMARA; RATTUS; RATTUS NORVEGICUS;

EID: 59649111704     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2008.10.011     Document Type: Article

References (50)

1. ® (STW 5) in intestinal smooth muscle. Phytomedicine 13 Suppl. 1 (2006) 67-74
2. Barbara G., De Giorgio R., Stanghellini V., and Corinaldesi R. A role for inflammation in irritable bowel syndrome?. Gut 51 Suppl. 1 (2002) i41-i44
3. Cho C.H. Current roles of nitric oxide in gastrointestinal disorders. J. Physiol. Paris 95 (2001) 253-256
4. Collins S.M. Peripheral mechanisms of symptom generation in irritable bowel syndrome. Can. J. Gastroenterol. 15 Suppl. B (2001) 14B-16B
5. de Waal M.R., Haanen J., Spits H., Roncarolo M.G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., and de Vries J.E. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J. Exp. Med. 174 (1991) 915-924
6. Elson C.O., Sartor R.B., Tennyson G.S., and Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 109 (1995) 1344-1367
7. Escandell J.M., Recio M.C., Manez S., Giner R.M., Cerdá-Nicolás M., and Ríos J.L. Cucurbitacin R reduces the inflammation and bone damage associated with adjuvant arthritis in Lewis rats by suppression of tumor necrosis factor-alpha in T lymphocytes and macrophages. J. Pharmacol. Exp. Ther. 320 (2007) 581-590
8. Feldman L.J., Aguirre L., Ziol M., Bridou J.P., Nevo N., Michel J.B., and Steg P.G. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 101 (2000) 908-916
9. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115 (1998) 182-205
10. ®). Phytomedicine 13 Suppl. 1 (2006) 45-50
11. Goldman M., and Velu T. Interleukin-10 and its implications for immunopathology. Adv. Nephrol. Necker Hosp. 24 (1995) 79-90
12. Grage-Gribenow E., Lorenzen D., Fetting R., and Flad H.D. Phenotypical and functional characterization of Fc gamma receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high accessory and antiviral activity. Eur. J. Immunol. 23 (1993) 3126-3135
13. Grossi L., McHugh K., and Collins S.M. On the specificity of altered muscle function in experimental colitis in rats. Gastroenterology 104 (1993) 1049-1056
14. Gundermann K.J., Godehardt E., and Ulbrich M. Efficacy of a herbal preparation in patients with functional dyspepsia: a meta-analysis of double-blind, randomized, clinical trials. Adv. Ther. 20 (2003) 43-49
15. Hanisch J., Bock P., and Vinson B. Die Wirksamkeit und Unbedenklichkeit von STW 5 versus Metoclopramid oral bei funtioneller Dyspepsie unter Praxisbedingung (2005), Deutsche Gesellschaft für Innere Medizin: 111 Internistenkongress, Wiesbaden, Abstractband
16. ®) and its components. Phytomedicine 13 Suppl. 1 (2006) 75-79
17. Heuschkel R.B. New immunologic treatments for inflammatory bowel disease. Curr. Opin. Gastroenterol. 16 (2000) 565-570
18. Hohenester B., Ruhl A., Kelber O., and Schemann M. The herbal preparation STW 5 (lberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol. Motil. 16 (2004) 765-773
19. Klingenberg, M., 2006. Induktion der Endotoxin Toleranz und Kreuztoleranz in der Darmmuskularis der Ratte. Dissertation.
20. Kok M.R., Yamano S., Lodde B.M., Wang J., Couwenhoven R.I., Yakar S., Voutetakis A., Leroith D., Schmidt M., Afione S., Pillemer S.R., Tsutsui M.T., Tak P.P., Chiorini J.A., and Baum B.J. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Hum. Gene Ther. 14 (2003) 1605-1618
21. Linden J. New insights into the regulation of inflammation by adenosine. J. Clin. Invest. 116 (2006) 1835-1837
22. Madisch A., Melderis H., Mayr G., Sassin I., and Hotz J. A plant extract and its modified preparation in functional dyspepsia. Results of a double-blind placebo controlled comparative study. Z. Gastroenterol. 39 (2001) 511-517
23. Mazighi M., Pelle A., Gonzalez W., Mtairag e.M., Philippe M., Hénin D., Michel J.B., and Feldman L.J. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H866-H871
24. Michael S., Kelber O., Vinson B., and Nieber K. Herbal preparations STW 5 and STW 6 inhibit ileal inflammation-mediated motility disorders. Gut 55 Suppl. V (2006) A1-A352
25. Neurath M.F. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives. Arch. Immunol. Ther. Exp. (Warsz) 48 (2000) 81-84
26. Nicolay K. Funktionelle Gastroenteropathien im therapeutischen Blindvergleich von Metoclopramid mit dem Pytopharmakon Iberogast. Gastro-Entero-Hepatolology 2 (1984) 24-28
27. Pallone F., and Monteleone G. Mechanisms of tissue damage in inflammatory bowel disease. Curr. Opin. Gastroenterol. 17 (2001) 307-312
28. Petit-Bertron A.F., Pedron T., Gross U., Coppée J.Y., Sansonetti P.J., Cavaillon J.M., and Adib-Conquy M. Adherence modifies the regulation of gene expression induced by interleukin-10. Cytokine 29 (2005) 1-12
29. Pfaffl M.W., Horgan G.W., and Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of real-time PCR. Nucleic. Acids Res. 30 (2002) E36
30. Reichling J., and Saller R. Iberis amara L. (bitter candytuft) - profile of a medicinal plant. Forsch Komplementarmed Klass Naturheilkd 9 Suppl. 1 (2002) 21-33
31. Rietschel E.T., Brade H., Holst O., Brade L., Müller-Loennies S., Mamat U., Zähringer U., Beckmann F., Seydel U., Brandenburg K., Ulmer A.J., Mattern T., Heine H., Schletter J., Loppnow H., Schönbeck U., Flad H.D., Hauschildt S., Schade U.F., Di Padova F., Kusumoto S., and Schumann R.R. Bacterial endotoxin: chemical constitution, biological recognition, host response, and immunological detoxification. Curr. Top. Microbiol. Immunol. 216 (1996) 39-81
32. Romeis, B., 1989. Van Gieson Färbung in Mikroskopische Technik, vol. 17. Urban & Schwarzenberg Verlag, München, pp. 236-504.
33. Rösch W., Vinson B., and Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z. Gastroenterol. 40 (2002) 401-408
34. Rösch W., Liebregts T., Gundermann K.J., Vinson B., and Holtmann G. Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5. Phytomedicine 13 Suppl. 1 (2006) 114-121
35. Sassin I., and Buchert D. Efficacy and tolerability of the herbal preparation Iberogast in the therapy of functional dyspepsia. Phytomedicine 7 Suppl. 2 (2000) 91-92
36. ®) and its components. Phytomedicine 13 Suppl. 1 (2006) 36-44
37. Selve, N., 1992. Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. Agents Actions Spec no.: C15-C17.
38. Selzman C.H., McIntyre Jr. R.C., Shames B.D., Whitehill T.A., Banerjee A., and Harken A.H. Interleukin-10 inhibits human vascular smooth muscle proliferation. J. Mol. Cell Cardiol. 30 (1998) 889-896
39. Sethi A.K., and Sarna S.K. Colonic motor activity in acute colitis in conscious dogs. Gastroenterology 100 (1991) 954-963
40. ®) and its components to intestinal 5-HT, muscarinic M(3), and opioid receptors. Phytomedicine 13 Suppl. V (2006) 51-55
41. Sitkovsky M.V., Lukashev D., Apasov S., Kojima H., Koshiba M., Caldwell C., Ohta A., and Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors 1. Annu. Rev. Immunol. 22 (2004) 657-682
42. Snape Jr. W.J., Williams R., and Hyman P.E. Defect in colonic smooth muscle contraction in patients with ulcerative colitis. Am. J. Physiol. 261 (1991) G987-G991
43. Soderholm J.D., Streutker C., Yang P.C., Paterson C., Singh P.K., McKay D.M., Sherman P.M., Croitoru K., and Perdue M.H. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 53 (2004) 1817-1824
44. Stokkers P.C., and Hommes D.W. New cytokine therapeutics for inflammatory bowel disease. Cytokine 28 (2004) 167-173
45. Warstat C., and Nieber K. Influence of adenosine A1-and A2A-receptor ligands on experimentally induced inflammation in the rat ileum. N.-S. Arch. Pharmacol. 367 Suppl. 1 (2004) R33,119
46. Warstat C., Grahnert A., Hauschildt S., and Nieber K. Role of adenosine receptors in inflammatory processes of the gastrointestinal system. N.-S. Arch. Pharmacol. 369 Suppl. 2 (2004) R28,112
47. ®). Phytomedicine 13 Suppl. 1 (2006) 20-35
48. Willems F., Marchant A., Delville J.P., Gérard C., Delvaux A., Velu T., de Boer M., and Goldman M. Interleukin-10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur. J. Immunol. 24 (1994) 1007-1009
49. Yoshidome H., Kato A., Edwards M.J., and Lentsch A.B. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: implications of a central role for nuclear factor kappaB. Hepatology 30 (1999) 203-208
50. Zimmerman M.A., Reznikov L.L., Raeburn C.D., and Selzman C.H. Interleukin-10 attenuates the response to vascular injury. J. Surg. Res. 121 (2004) 206-213